Amer Zeidan, Professor of Medicine and Chief of Hematologic Malignancies at Yale Cancer Center, shared on LinkedIn:
“Our most recent paper shows that patients with acute myeloid leukemia who received azacitidine-venetoclax spend one third of their lives after diagnosis in health care settings.
We need to do better, and total oral therapy might help with that.”
Title: Time burden and treatment patterns of patients with newly diagnosed acute myeloid leukemia receiving parenteral hypomethylating agents in combination with venetoclax
Authors: Amer M. Zeidan, Ruizhi Zhao, Arthur Voegel, Dina Christensen, Maryia Zhdanava, Anabelle Tardif-Samson, Claire Vanden Eynde, Harold Keer, Dominic Pilon, Fang Sun.
Other articles about Amer Zeidan on OncoDaily.